Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 5/20 | 0.43 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935208 | 0.92 | CA2 (0.66) | CA2CA1MAPK1 | |
| SCHEMBL20987770 | 0.92 | CA2 (0.50) | CA2CA1GPR84FFAR1MMP3 | |
| SCHEMBL21250716 | 0.92 | CA2 (0.50) | CA2CA1GPR84FFAR1MMP3 | |
| SCHEMBL23082924 | 0.91 | CA2 (0.53) | CA2CA1GPR84FFAR1MMP3 | |
| SCHEMBL8240572 | 0.83 | GPR84 (0.57) | CA2GPR84FFAR1MMP3MMP1 | |
| SCHEMBL8233988 | 0.83 | GPR84 (0.57) | CA2GPR84FFAR1MMP3MMP1 | |
| SCHEMBL12058916 | 0.82 | TSHR (0.52) | CA2CA1MAPK1 | |
| SCHEMBL21452007 | 0.81 | CA1 (0.50) | CA2CA1GPR84FFAR1 | |
| SCHEMBL20915253 | 0.81 | CA2 (0.85) | CA2CA1MAPK1MMP3MMP1 | |
| SCHEMBL20936460 | 0.81 | CA2 (0.85) | CA2CA1MAPK1MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450301-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, AIFM1, BCL2 | CA2 4216/4885CA1 3532/4885MAPK1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.